As for the PTC patients, studies on BRAF inhibitors have mainly focused on radioactive iodine refractory differentiated thyroid cancer, and relevant clinical trials are in progress (NCT02145143; NCT04462471; NCT04940052; NCT01947023; NCT04554680; NCT05182931). Here, BRAF is linked to differentiated thyroid carcinoma.